{"id":"bepridil","rwe":[],"tags":[{"label":"High Risk QT Prolonging Agents","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent P/Q-type calcium channel subunit alpha-1A","category":"target"},{"label":"CACNA1A","category":"gene"},{"label":"KCNH2","category":"gene"},{"label":"SCN1A","category":"gene"},{"label":"C08EA02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Angina pectoris","category":"indication"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":96.452,"date":"","count":34,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=96)"},{"llr":51.331,"date":"","count":12,"signal":"Cardiac tamponade","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=51)"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"},{"url":"/drug/bumetanide","drug":"bumetanide","action":"Avoid combination","effect":"May interact with Bumetanide","source":"DrugCentral","drugSlug":"bumetanide"},{"url":"/drug/erythromycin","drug":"erythromycin","action":"Avoid combination","effect":"May interact with Erythromycin","source":"DrugCentral","drugSlug":"erythromycin"},{"url":"/drug/fosamprenavir","drug":"fosamprenavir","action":"Avoid combination","effect":"May interact with Fosamprenavir","source":"DrugCentral","drugSlug":"fosamprenavir"},{"url":"/drug/furosemide","drug":"furosemide","action":"Avoid combination","effect":"May interact with Furosemide","source":"DrugCentral","drugSlug":"furosemide"},{"url":"/drug/hydrochlorothiazide","drug":"hydrochlorothiazide","action":"Avoid combination","effect":"May interact with Hydrochlorothiazide","source":"DrugCentral","drugSlug":"hydrochlorothiazide"},{"url":"/drug/ritonavir","drug":"ritonavir","action":"Monitor closely","effect":"May interact with Ritonavir","source":"DrugCentral","drugSlug":"ritonavir"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BEPRIDIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:49:36.907503+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:49:42.227290+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEPRIDIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:49:42.648112+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Voltage-gated calcium channel blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:43.708088+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200382/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:43.356998+00:00"}},"allNames":"org 5730","offLabel":[],"synonyms":["bepridil hydrochloride hydrate","bepridil hydrochloride","bepridil","dl-Bepridil","(+/-)-Bepridil","bepricol","Org 5730","bepridil monohydrochloride monohydrate","bepridil monohydrochloride","cordium","bepridil HCl"],"timeline":[{"date":"1990-12-28","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Org 5730, also known as Bepridil, is a high-risk QT prolonging agent that was originally developed by Organon and is currently owned by a generic manufacturer. It is a small molecule that targets the voltage-dependent P/Q-type calcium channel subunit alpha-1A. Bepridil was FDA approved in 1990 for the treatment of angina pectoris. It has a half-life of 14.9 hours and bioavailability of 61%. Bepridil is off-patent and has no active Orange Book patents.","brandName":"Org 5730","ecosystem":[{"indication":"Angina pectoris","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atenolol","slug":"atenolol","company":"Alvogen Ipco Sarl"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"diltiazem","slug":"diltiazem","company":"Valeant Intl"}],"globalPrevalence":112000000}],"mechanism":{"target":"Voltage-dependent P/Q-type calcium channel subunit alpha-1A","novelty":"Follow-on","targets":[{"gene":"CACNA1A","source":"DrugCentral","target":"Voltage-dependent P/Q-type calcium channel subunit alpha-1A","protein":"Voltage-dependent P/Q-type calcium channel subunit alpha-1A"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"},{"gene":"HCN4","source":"DrugCentral","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4"},{"gene":"CACNA1H","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1H","protein":"Voltage-dependent T-type calcium channel subunit alpha-1H"},{"gene":"KCNQ4","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily KQT member 4","protein":"Potassium voltage-gated channel subfamily KQT member 4"},{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha"},{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1C","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"}],"modality":"Small Molecule","drugClass":"High Risk QT Prolonging Agents","explanation":"","oneSentence":"","technicalDetail":"Bepridil is a selective blocker of the L-type calcium channel, specifically targeting the P/Q-type calcium channel subunit alpha-1A, which is involved in the regulation of cardiac contractility and vascular tone."},"commercial":{"launchDate":"1990","_launchSource":"DrugCentral (FDA 1990-12-28, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/342","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BEPRIDIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEPRIDIL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:56:24.930109","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:49:45.000695+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"quinidine","drugSlug":"quinidine","fdaApproval":"1950-07-12","genericCount":35,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"bepridil","indications":{"approved":[{"name":"Angina pectoris","source":"DrugCentral","snomedId":194828000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":112000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"quinidine","brandName":"quinidine","genericName":"quinidine","approvalYear":"1950","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT05711693","phase":"NA","title":"Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2023-03-13","conditions":["Hypertension","Aortic Aneurysm","Bicuspid Aortic Valve","Marfan Syndrome","Aortic Dilatation"],"enrollment":100,"completionDate":"2024-06-19"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000147653","MMSL":"4267","NDDF":"003562","UNII":"755BO701MA","VUID":"4019549","CHEBI":"CHEBI:3061","VANDF":"4019549","INN_ID":"3465","RXNORM":"1436","UMLSCUI":"C0005116","chemblId":"CHEMBL1200382","ChEMBL_ID":"CHEMBL1008","KEGG_DRUG":"D00631","DRUGBANK_ID":"DB01244","PDB_CHEM_ID":" BEP","PUBCHEM_CID":"2351","SNOMEDCT_US":"108530004","IUPHAR_LIGAND_ID":"2337","SECONDARY_CAS_RN":"74764-40-2","MESH_DESCRIPTOR_UI":"D015764"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"14.9 hours","clearance":"8.7 mL/min/kg","bioavailability":"61%","fractionUnbound":"0.001%","volumeOfDistribution":"10.1 L/kg"},"publicationCount":822,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C08EA02","allCodes":["C08EA02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1990","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:49:45.000695+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}